
Co-Diagnostics (CODX) Stock Forecast & Price Target
Co-Diagnostics (CODX) Analyst Ratings
Bulls say
Co-Diagnostics Inc's promising outlook is bolstered by the expanding market for respiratory infectious disease diagnostics, particularly in the Middle East, driven by significant investments in the Kingdom of Saudi Arabia. The company’s strategic partnership with Arabian Eagle Manufacturing to commercialize its Co-Dx technologies across 19 nations positions it favorably for growth in a region with high demand for affordable molecular diagnostics. Furthermore, Co-Diagnostics is enhancing its Co-Dx PCR platform, indicating a commitment to innovation and regulatory compliance, which could further broaden its market opportunities beyond tuberculosis.
Bears say
Co-Diagnostics Inc faces multiple risks that contribute to a negative financial outlook, including potential failures in clinical evaluations and difficulty in securing necessary regulatory clearances for its products, which could hinder market entry. Additionally, the company reported significantly low revenue of $145,000 for the third quarter of 2025, alongside a substantial net loss of $5.9 million, translating to a loss of $0.16 per share, indicating ongoing financial struggles. Concerns about further dilution due to the need for additional funding at possibly unfavorable terms further exacerbate the perception of financial instability within the company.
This aggregate rating is based on analysts' research of Co-Diagnostics and is not a guaranteed prediction by Public.com or investment advice.
Co-Diagnostics (CODX) Analyst Forecast & Price Prediction
Start investing in Co-Diagnostics (CODX)
Order type
Buy in
Order amount
Est. shares
0 shares